177 related articles for article (PubMed ID: 21129496)
1. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes?
Jager MJ; Ly LV; El Filali M; Madigan MC
Prog Retin Eye Res; 2011 Mar; 30(2):129-46. PubMed ID: 21129496
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1414-21. PubMed ID: 11381040
[TBL] [Abstract][Full Text] [Related]
3. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
4. [Tumor angiogensis in uveal melanoma. Role of vascular endothelial growth factor (VEGF)].
Proniewska-Skretek E; Mariak Z
Klin Oczna; 2004; 106(4-5):682-5. PubMed ID: 15646494
[TBL] [Abstract][Full Text] [Related]
5. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
6. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
7. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.
Mäkitie T; Carpén O; Vaheri A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2442-9. PubMed ID: 11581181
[TBL] [Abstract][Full Text] [Related]
8. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma.
Maat W; Ly LV; Jordanova ES; de Wolff-Rouendaal D; Schalij-Delfos NE; Jager MJ
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):505-10. PubMed ID: 18234992
[TBL] [Abstract][Full Text] [Related]
9. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity.
Chen X; Maniotis AJ; Majumdar D; Pe'er J; Folberg R
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2533-9. PubMed ID: 12147581
[TBL] [Abstract][Full Text] [Related]
10. [Characteristics of the immune status of patients with uveal melanoma during the performance of organ-preserving treatment].
Maletskiĭ AP; Vit VV; Vanichkin AA
Oftalmol Zh; 1989; (6):341-6. PubMed ID: 2622598
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor-associated vasculatures in uveal and cutaneous melanomas.
Bhat P; Jakobiec FA; Folberg R
Semin Ophthalmol; 2009; 24(3):166-71. PubMed ID: 19437353
[TBL] [Abstract][Full Text] [Related]
12. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
[TBL] [Abstract][Full Text] [Related]
13. Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey.
Ly LV; Odish OF; Wolff-Rouendaal Dd; Missotten GS; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):658-65. PubMed ID: 19797220
[TBL] [Abstract][Full Text] [Related]
14. Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha and TGF-beta.
Woodward JK; Elshaw SR; Murray AK; Nichols CE; Cross N; Laws D; Rennie IG; Sisley K
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3144-52. PubMed ID: 12356817
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
[TBL] [Abstract][Full Text] [Related]
16. Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis.
Notting IC; Buijs JT; Que I; Mintardjo RE; van der Horst G; Karperien M; Missotten GS; Jager MJ; Schalij-Delfos NE; Keunen JE; van der Pluijm G
Invest Ophthalmol Vis Sci; 2005 May; 46(5):1581-7. PubMed ID: 15851554
[TBL] [Abstract][Full Text] [Related]
17. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors.
Al-Jamal RT; Kivelä T
Curr Eye Res; 2006 Jan; 31(1):57-67. PubMed ID: 16421020
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic role of morphological characteristics of the immune response in uveal melanoblastomas of various cellular types].
Vit VV
Arkh Patol; 1983; 45(7):25-30. PubMed ID: 6625934
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.
de Lange MJ; Nell RJ; Lalai RN; Versluis M; Jordanova ES; Luyten GPM; Jager MJ; van der Burg SH; Zoutman WH; van Hall T; van der Velden PA
Mol Cancer Res; 2018 Dec; 16(12):1902-1911. PubMed ID: 30093564
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Clin Cancer Res; 2006 Feb; 12(4):1383-91. PubMed ID: 16489097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
